Showing results (11-20 of 147) with videos related to
Sort By:
Pageof 15
Journal of Clinical Psychopharmacology|October 1, 1992
Clomipramine plasma levels among depressed outpatients in Benin, west Africa: drug compliance and comparison with Caucasian patientsG Bertschy, S VandelL'Encephale|January 1, 1991
[The link between suicide and depression. Epidemiologic aspects]G Bertschy, S VandelPharmacological Research|June 1, 1995
Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patientsS Vandel, G Bertschy, P Baumann, et al.L'Encephale|May 1, 1996
[Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration]B Bonin, G Bertschy, P Baumann, et al.European Journal of Clinical Pharmacology|January 19, 2000
Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypesP Vandel, E Haffen, S Vandel, et al.Therapie|November 1, 1994
[A case of metabolic interaction: amitriptyline, fluoxetine, antitubercular agents]G Bertschy, S Vandel, M C PeraultL'Encephale|January 1, 1990
[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]G Bertschy, S Vandel, J M Jounet, et al.Therapeutic Drug Monitoring|January 1, 1988
Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patientsS Vandel, G Bertschy, J M Jounet, et al.Medical Hypotheses|December 1, 1996
CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effectsP Vandel, B Bonin, S Vandel, et al.L'Encephale|August 6, 1999
[Clinical tolerance of a new antidepressant -- milnacipran]W Regina, P Vandel, S Vandel, et al.Pageof 15